Biotech Values

[DewDiligence]

ABT acquires CSII for $20/sh cash—a 50% premium to today’s closing price:

• Abbott will gain an innovative, complementary solution in treating vascular disease through CSI's leading atherectomy system, which prepares vessels for angioplasty or stenting to restore blood flow

• CSI's offering will support Abbott's ability to provide better care for patients with peripheral and coronary artery disease

The nominal deal value is $890M. Closing requires approval of CSII’s shareholders, but that’s a fait accompli.

The Medical Devices business segment is ABT’s largest, accounting for 37% of corporate sales in 4Q22 (#msg-171028943).

ABT’s 2023 financial guidance remains unchanged—see #msg-171028771 for details.